新型抗癫痫药物进展报告。第二届埃拉特会议总结。

Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference.

作者信息

Stables J P, Bialer M, Johannessen S I, Kupferberg H J, Levy R H, Loiseau P, Perucca E

机构信息

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Epilepsy Res. 1995 Nov;22(3):235-46. doi: 10.1016/0920-1211(95)00054-2.

DOI:10.1016/0920-1211(95)00054-2

PMID:8991791

Abstract

The Second Eilat Conference on New Antiepileptic Drugs was held at the King Solomon's Palace Hotel from October 31 to November 3, 1994. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss new trial designs, drug approval, early use of new antiepileptic drugs, and new drugs in development. Over the last six years, several novel antiepileptic drugs have been introduced worldwide, and new information on their safety and efficacy has become available. These include felbamate, gabapentin, lamotrigine, oxcarbazepine, and vigabatrin. Drugs in development include those at an advanced stage, such as topiramate and tiagabine, as well as those just entering clinical trials, such as remacemide and levetiracetam. The following is a summary of the presentations for drugs in development and newly marketed drugs. The meeting concluded with a presentation, 'Still Searching for the Magic Bullet'.

摘要

第二届埃拉特新型抗癫痫药物会议于1994年10月31日至11月3日在所罗门王宫殿酒店举行。来自20个国家的癫痫学家和科学家参加了此次会议，会议旨在讨论新的试验设计、药物审批、新型抗癫痫药物的早期使用以及正在研发的新药。在过去六年里，全球已推出了几种新型抗癫痫药物，并且有了关于它们安全性和有效性的新信息。这些药物包括非氨酯、加巴喷丁、拉莫三嗪、奥卡西平以及氨己烯酸。正在研发的药物包括处于后期阶段的药物，如托吡酯和噻加宾，以及刚进入临床试验阶段的药物，如瑞玛西胺和左乙拉西坦。以下是关于正在研发的药物和新上市药物的报告总结。会议最后进行了一场题为“仍在寻找神奇药物”的演讲。